Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04547998 · ClinicalTrials.gov registry record · NA
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
A NA study, sponsored by Avita Medical.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT04547998: Completed NA study, sponsored by Avita Medical.
NCT04547998 is a NA study that has completed, run by Avita Medical. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04547998, a NA study, has completed, sponsored by Avita Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
Primary Outcome
Repigmentation was evaluated by qualified members of a Central Review Committee.
Interventions
- DEVICE Control Intervention (UVB)
- DEVICE Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
What the finished NCT04547998 record still lists
NCT04547998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Control Intervention (UVB) is the first listed.
NCT04547998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04547998 about?
NCT04547998 is a clinical study titled "Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions". This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
What is the current status of trial NCT04547998?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2020-09-10. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT04547998?
The interventions under investigation include: Control Intervention (UVB) (DEVICE), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB) (DEVICE).
Who is sponsoring clinical trial NCT04547998?
This trial is sponsored by Avita Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04547998's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI